Yes, overtreatment with levothyroxine can cause muscle tension and muscle spasm
Overtreatment with levothyroxine directly causes muscle spasm and muscle weakness as manifestations of iatrogenic hyperthyroidism. This is clearly documented in the FDA drug label as an adverse reaction of therapeutic overdosage 1.
Mechanism and Clinical Presentation
When levothyroxine dosing exceeds physiologic needs, it creates a state of iatrogenic hyperthyroidism (thyrotoxicosis). The FDA explicitly lists muscle spasm and muscle weakness among the musculoskeletal adverse reactions associated with levothyroxine overtreatment 1. Additional neuromuscular manifestations include:
- Tremors
- Muscle weakness
- Muscle spasm
- Hyperactivity and nervousness (which can manifest as increased muscle tension)
Evidence from Drug Labels
The FDA labeling is unequivocal that these musculoskeletal symptoms occur "primarily due to therapeutic overdosage" 1. The mechanism involves the hypermetabolic state induced by excess thyroid hormone, which affects skeletal muscle contractility and function 1.
Clinical Implications for Monitoring
The key to preventing these symptoms is avoiding overtreatment through proper TSH monitoring. Guidelines emphasize that overtreatment occurs in approximately 20% of patients on thyroid hormone therapy 2. The principal adverse consequences of overtreatment include:
- Cardiovascular effects (particularly in elderly patients)
- Skeletal effects (accelerated bone loss in postmenopausal women)
- Musculoskeletal symptoms including the muscle tension you're asking about
Diagnostic Approach
If a patient on levothyroxine presents with muscle tension or spasm:
- Check TSH immediately - Suppressed TSH (<0.1 mIU/L) indicates overtreatment
- Assess for other hyperthyroid symptoms: tremor, palpitations, heat intolerance, weight loss, insomnia, anxiety 1
- Review the dosing history - Recent dose increases or compliance issues with excessive intake
Management Algorithm
When overtreatment is confirmed:
- Reduce the levothyroxine dose or temporarily withhold therapy
- Recheck TSH in 6-8 weeks after dose adjustment
- Target TSH within the reference range (typically 0.5-4.5 mIU/L for most patients) 2
- Symptoms should resolve as euthyroidism is restored
Important Caveats
Recent systematic review data confirms that adverse events, including musculoskeletal symptoms, occur primarily when TSH is suppressed 3. In properly dosed patients maintaining euthyroid TSH levels, these symptoms are rare and may reflect nocebo effects rather than true drug toxicity 3.
The clinical context matters: muscle symptoms in a patient with normal TSH are unlikely to be levothyroxine-related, whereas the same symptoms with suppressed TSH strongly suggest overtreatment 3.